MeMed secures $93 million for tests to identify viral and bacterial infections

While most infectious disease tests look at a sample for the presence of a specific pathogen, MeMed Diagnosis collects evidence from the immune system itself and helps identify the culprit by measuring the body’s response to invaders.

The company obtained Food and Drug Administration (FDA) clearance for the platform last September. Now, MeMed has raised $93 million to help scale up manufacturing and bring its diagnostic tests to US hospitals and clinics.

MeMed methods allow health care providers to diagnose conditions in adults and children even if the site of infection is unknown or inaccessible using conventional tests.

BV Point of Care Testing and the company’s flagship platform can also distinguish between bacterial and viral infections to help avoid misuse of antibiotics in situations where they do not provide any benefit and instead potentially contribute to the growth of antimicrobial resistance.

Separately, the company developed a test to predict which patients might be more likely to develop severe cases of COVID-19 and obtained a CE marking for use in Europe last year.

RELATED: MeMed raises $70M to diagnose immune system-based infections

Israel-based MeMed’s latest funding includes support from Horizons Ventures, Shavit Capital, Social Capital, La Maison Partners, Touchwood Capital, Caesarea Medical Holdings, Union Tech Ventures, ClaI Insurance, Phoenix Insurance, Poalim Equity and Western Technology Investment.

Return on venture capital brings the company’s total lifetime fundraising to more than $200 million, including funding from the US Department of Defense and the European Commission.

Late last year, the company announced the results of a study of more than 1,000 children brought to hospital emergency rooms with fevers of unknown cause as well as respiratory infections.

While bacterial and viral infections can be indistinguishable, and often lead to the prescription of unnecessary antibiotics for children with viral infections, the 15-minute MeMed blood test measures levels of three immune system proteins that can vary between the body’s response to each type of blood. infection.

The prospective study found that the company’s test can accurately determine whether bacteria are the main cause of the fever, even if a positive PCR test result for the virus. At the same time, the diagnosis showed that it can reduce the overuse of antibiotics in children with viral infections. The results were published in the journal Clinical Microbiology and Infection.


Leave a Comment